Lucid Diagnostics Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.7M | $4.3M | $2.4M | $377,000 | $500,000 |
| Gross profit | — | — | — | $377,000 | $500,000 |
| Operating income | -$49.6M | -$46.1M | -$48.5M | -$56.3M | -$27.4M |
| Operating expenses | — | $50.4M | $50.9M | $56.6M | $27.9M |
| Cost of revenue | $6.7M | $7.1M | — | $100.0M | $585,000 |
| Cash from operations | -$46.5M | -$44.1M | -$32.8M | -$29.7M | -$17.7M |
| Capital expenditure | $197,000 | $296,000 | — | $3.2M | $862,000 |
| Free cash flow | -$46.7M | -$44.4M | — | -$32.9M | -$18.5M |
| Total assets | $40.4M | $30.7M | $27.3M | $32.5M | $59.0M |
| Total liabilities | $29.5M | $25.3M | $29.6M | $9.5M | $4.3M |
Shares outstanding 203.1M · Free float 77.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.